BIOLASE (NASDAQ:BIOL) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report report published on Monday morning. The brokerage issued a sell rating on the medical technology company’s stock.

Several other equities research analysts have also recently commented on BIOL. Maxim Group cut shares of BIOLASE from a strong-buy rating to a hold rating in a research report on Friday, May 24th. Ascendiant Capital Markets decreased their price target on shares of BIOLASE from $3.50 to $2.00 and set a buy rating on the stock in a research note on Tuesday, September 3rd. Finally, Benchmark restated a speculative buy rating and set a $0.40 target price on shares of BIOLASE in a research report on Monday, August 12th.

BIOLASE Price Performance

Shares of BIOL stock opened at $0.06 on Monday. BIOLASE has a 12-month low of $0.04 and a 12-month high of $3.57. The firm has a market capitalization of $1.90 million, a price-to-earnings ratio of 0.00 and a beta of 0.66. The firm has a fifty day moving average of $0.07 and a 200-day moving average of $0.12.

BIOLASE (NASDAQ:BIOL) last posted its quarterly earnings data on Thursday, August 8th. The medical technology company reported ($0.08) EPS for the quarter. The company had revenue of $11.56 million during the quarter. BIOLASE had a negative net margin of 41.65% and a negative return on equity of 1,782.73%.

Hedge Funds Weigh In On BIOLASE

A hedge fund recently raised its stake in BIOLASE stock. Virtu Financial LLC lifted its position in shares of BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 143,537 shares of the medical technology company’s stock after buying an additional 131,248 shares during the quarter. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 at the end of the most recent reporting period. Institutional investors own 8.79% of the company’s stock.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.